Revisão |
As possíveis fontes fisiopatológicas da fibromialgia e suas importâncias como alvos para tratamento |
The possible physiopathological sources of fibromyalgia and its importance as targets for treatment |
Paulo Augusto Alambert |
Professor titular de Reumatologia. Professor assistente da disciplina de Propedêutica. Membro do grupo de Clínica Médica da Faculdade de Ciências Médicas de Santos (Unilus). Professor assistente de Reumatologia da Universidade Metropolitana de Santos (Unimes). |
Lucas Ribeiro dos Santos Rafael Costa Hime Fernando Focaccia Povoa Elimar Rodrigues Alexandre Filho |
Faculdade de Ciências Médicas de Santos – Unilus. |
Andréa Carla de Souza Contenças |
Faculdade de Ciências da Saúde -Medicina – Unimes. |
Endereços: UNILUS: Rua Oswaldo Cruz, 179 – CEP 11045-101 – Boqueirão, Santos/SP – Brasil – Tel.: (13) 3221-3252. UNIMES: Rua da Constituição, 374 – CEP 11015-904 – Vila Nova, Santos/SP – Brasil – Tel.: (13) 3226-3400. Trabalho realizado na Faculdade de Ciências Médicas de Santos (Unilus) e Universidade Metropolitana de Santos (Unimes). Endereço para correspondência: Lucas Ribeiro dos Santos. Rua Comendador Alfaya Rodrigues, 180, CEP 11025-150 – Santos – SP – E-mail: [email protected] Recebido para publicação em 08/2007. Aceito em 02/2008. Copyright Moreira Jr. Editora. Todos os direitos reservados. Indexado na Lilacs Virtual sob nº LLXP: S0034-72642009001900001 |
Unitermos: fibromialgia, fisiopatologia, inflamatório, neuroendócrino, NMDA. |
Unterms: fibromyalgia, physiopathology, inflammatory, neuroendocrine, NMDA |
|
Numeração de páginas na revista impressa: 3 à 10 |
Bibliografia |
1. Bennet RM, Smythe HA, Wolfe F. Recognizing fibromyalgia. Patient Care. 1989 23:60-83. 2. Helfenstein M, Feldman D. Síndrome da fibromialgia: características clínicas e associações com outras síndromes disfuncionais. Rev Bras Reumatol. 2002 Jan/Fev 42(1):8-14. 3. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995 Jan 38(1):19-28. 4. Wolfe F, Anderson J, Harkness D et al. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum 1997 40:1560-1570. 5. Wolfe F, Anderson J, Harkness D et al. Work and disability status of persons with fibromyalgia. J Rheumatol 1997 24:1171-1178. 6. Doron Y, Peleg R, Peleg A, Neumann L, Buskila D. The clinical and economic burden of fibromyalgia compared with diabetes mellitus and hypertension among Bedouin women in the Negev. Fam Pract. 2004 Aug 21(4):415-9. 7. Macfarlane GJ, McBeth J, Silman AJ. Widespread body pain and mortality: prospective population based study. BMJ. 2001 Sep 22 323(7314):662- 5. 8. Aronoff GM. Myofascial pain syndrome and fibromyalgia: a critical assessment and alternate view. J Clin Pain. 1998 14:74-85. 9. McBeth J, Macfarlane GJ, Benjamin S, Silman AJ. Features of somatization predict the onset of chronic widespread pain: results of a large population- based study. Arthritis Rheum. 2001 Apr 44(4):940-6. 10. Croft P, Rigby AS, Boswel R, Schollum J, Silman A. The prevalence of chronic widespread pain in the general population. J Rheumatol 1993,20:710-3. 11. Hunt IM, Silman AJ, Benjamin S, McBeth J, Macfarlane GJ. The prevalence and associated features of chronic widespread pain in the community using the “Manchester” definition of chronic widespread pain. Rheumatology 1999,38:275-9.12. White KP, Nielson WR, Harth M, Ostbye T, Speechley M. Chronic widespread musculoskeletal pain with or without fibromyalgia: psychological distress in a representative community adult sample. J Rheumatol. 2002 Mar 29(3):588-94. 13. Arnold LM, Hudson JI, Keck PE, Auchenbach MB, Javaras KN, Hess EV. Comorbidity of fibromyalgia and psychiatric disorders. J Clin Psychiatry. 2006 Aug 67(8):1219-25. 14. Raphael KG, Janal MN, Nayak S, Schwartz JE, Gallagher RM. Psychiatric comorbidities in a community sample of women with fibromyalgia. Pain. 2006 Sep 124(1-2):117-25. 15. Bergman S. Psychosocial aspects of chronic widespread pain and fibromyalgia. Disabil Rehabil. 2005 Jun 17 27(12):675-83. 16. Brekke M, Hjortdahl P, Kvien TK. Severity of musculoskeletal pain: relations to socioeconomic inequality. Soc Sci Med. 2002 Jan 54(2):221-8. 17. Weissbecker I, Floyd A, Dedert E, Salmon P, Sephton S. Childhood trauma and diurnal cortisol disruption in fibromyalgia syndrome. Psychoneuroendocrinology. 2006 Apr 31(3):312-24. 18. Raphael KG, Janal MN, Nayak S. Comorbidity of fibromyalgia and posttraumatic stress disorder symptoms in a community sample of women. Pain Med. 2004 Mar 5(1):33-41. 19. Gupta A., Silman A.: Psychological stress and fibromyalgia: a review of evidence suggesting a neuroendocrine link. Arthritis Research and therapy, 6(3):98-106. 20. Kim SH, Jang TJ, Moon IS. Increased expression of N-methyl-D-aspartate receptor subunit 2D in the skin of patients with fibromyalgia. J Rheumatol. 2006 Apr 33(4):785-8. 21. Wallace DJ, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman MH. Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology. 2001 40:743-749. 22. Bradley LA, McKendree-Smith NL, Alberts KR, Alarcon GS, Mountz JM, Deutsch G. Use of neuroimaging to understand abnormal pain sensitivity in fibromyalgia. Curr Rheumatol Rep. 2000 Apr 2(2):141-8. 23. Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum. 2002 May 46(5):1333-1343. 24. Kwiatek R,Barnden L,Tedman R,Jarrett R,Chew J,Rowe C,Pile K. Regional cerebral blood flow in fibromyalgia: single-photon-emission computed tomography evidence of reduction in the pontine tegmentum and thalami. Arthritis Rheum. 2000 Dec 43(12):2823-33. 25. Mountz JM,Bradley LA,Modell JG,Alexander RW,Triana-Alexander, Aaron LA,Stewart KE,Alarcon GS,Mountz JD. Fibromyalgia in women. Abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum. 1995 Jul 38(7):926-38. 26. Guedj E, Taieb D, Cammilleri S, Lussato D, de Laforte C, Niboyet J, Mundler O. (99m)Tc-ECD brain perfusion SPECT in hyperalgesic fibromyalgia. Eur J Nucl Med Mol Imaging. 2007 Jan 34(1):130-4. 27. Taber KH, Rashid A, Hurley RA. Functional Anatomy of Central Pain. J Neuropsychiatry Clin Neurosci. 2001 Nov 13:437-440. 28. Gobbi LTB, Faria FP, Silveira CRA, Caetano MJD. Núcleos da base e controle motor: aspectos neurofisiológicos e evidências experimentais. Rev Bras Educ Fis Esp. 2006 Set 5(20):97-101. 29. Mathew NT. Tension-type headache. Curr Neurol Neurosci Rep. 2006 Mar 6(2):100-5. 30. Ploner M, Schnitzler A. Cortical representation of pain. Nervenarzt. 2004 Oct 75(10):962-9. 31. Zhang WT, Luo F, Han JS. Progress in the study of pain by brain imaging. Sheng Li Ke Xue Jin Zhan. 2001 Jul 32(3):209-14. 32. Sukhotinsky I, Hopkins DA, Lu J, Saper CB, Devor M. Movement suppression during anesthesia: neural projections from the mesopontine tegmentum to areas involved in motor control. J Comp Neurol. 2005 Sep 5 489(4):425-48. 33. Bajic D, Proudfit HK. Projections of neurons in the periaqueductal gray to pontine and medullary catecholamine cell groups involved in the modulation of nociception. J Comp Neurol. 1999 Mar 15 405(3):359-79. 34. Herraez-Baranda LA, Carretero J, Gonzalez-Sarmiento R, Rodriguez RE. Kappa opioid receptor is expressed in the rat cerebellar cortex. Cell Tissue Res. 2005 May 320(2):223-8. 35. Ma W, Chabot JG, Powell KJ, Jhamandas K, Dickerson IM, Quirion R. Delta opioid receptor localization in the rat cerebellum. Brain Res. 2002 Mar 22 931(1):100-5. 36. Ma W, Chabot JG, Powell KJ, Jhamandas K, Dickerson IM, Quirion R. Localization and modulation of calcitonin gene-related peptide-receptor component protein-immunoreactive cells in the rat central and peripheral nervous systems. Neuroscience. 2003 120(3):677-94. 37. Morara S, Wimalawansa SJ, Rosina A. Monoclonal antibodies reveal expression of the CGRP receptor in Purkinje cells, interneurons and astrocytes of rat cerebellar cortex. Neuroreport. 1998 Nov 16 9(16):3755-9. 38. Shibasaki H. Central mechanisms of pain perception. Suppl Clin Neurophysiol. 2004 57:39-49. 39. Cook DB, Lange G, Ciccone DS, Liu WC, Steffener J, Natelson BH. Functional imaging of pain in patients with primary fibromyalgia. J Rheumatol. 2004 Feb 31(2):364-78. 40. Karen D. Davis, Chun L. Kwan, Adrian P. Crawley, and David J. Mikulis. Functional MRI Study of Thalamic and Cortical Activations Evoked by Cutaneous Heat, Cold, and Tactile Stimuli. J Neurophysiol 1998 Sept 80(3): 1533-1546. 41. Friedman DP, Murray EA. Thalamic connectivity of the second somatosensory area and neighboring somatosensory fields of the lateral sulcus of the macaque. Com Neurol. 1986 252:348-373. 42. Raussel E, Jones EG. Chemicaly distinct compartments of the thalamic VPM nucleus in monkeys relay principal and spinal trigeminal pathways to different layers of the somatosensory cortex. J Neurosci. 1991 11:226- 237. 43. Shi T, Apkarian AV. Morphology of thalamocortical neurons projecting to the primary somatosensory cortex and their relantionship to spinalthalamic terminal in the squirrel monkey. J Comp Neurol. 1995 361:1-24. 44. Coghill RC, Talbot JD, Evans AC, Meyer E, Gjedde A, Bushnell MC, Duncan GH. Distributed processing of pain and vibration by the human brain. J Neurosci. 1994 14:4095-4108. 45. Jones AK, Brown WD, Friston KJ, Qi LY, Frackowiak RS. Cortical and subcortical localization of response to pain in man using positron emission tomography. Proc R Soc Lond B Biol Sci. 1991 244:39-44. 46. Ploghaus A, Tracey I, Gati JS, Clare S, Menon RS, Matthews PM, Rawlins JN. Dissociating pain from its anticipation in the human brain. Science. 1999 284:1979-1981. 47. Resstel LB, Correa FM. Involvement of the medial prefrontal cortex in central cardiovascular modulation in the rat. Auton Neurosci. 2006 Jun 30 126-127:130-8. 48. Oppenheimer S. Cerebrogenic cardiac arrhythmias: cortical lateralization and clinical significance. Clin Auton Res. 2006 Feb 16(1):6-11. 49. Oppenheimer SM, Gelb A, Girvin JP, Hachinski VC. Cardiovascular effects of human insular cortex stimulation. Neurology. 1992 Sep 42(9):1727- 32. 50. Resstel LB, Correa FM. Pressor and tachycardic responses evoked by microinjections of L-glutamate into the medial prefrontal cortex of unanaesthetized rats. Eur J Neurosci. 2005 May 21(9):2513-20. 51. Crofford LJ, Engleberg NC, Demitrack MA. Neurohormonal perturbations in fibromyalgia. Baillieres Clin Rheumatol. 1996 May 10(2):365-78. 52. Adler GK, Manfredsdottir VF, Creskoff KW. Neuroendocrine abnormalities in fibromyalgia. Curr Pain Headache Rep. 2002 Aug 6(4):289-98. 53. Russell IJ. Advances in fibromyalgia: possible role for central neurochemicals. Am J Med Sci. 1998 Jun 315(6):377-84. 54. Bennet RM, Cook DM, Clarck SR, Campbell SM, Burckhardt CS. Hipothalamic-Pituitary-Insulin like growth factor 1 axis disfunction in patients with fibromyalgia. J Rheumatol. 1997 24:1384-1389. 55. Leal-Cerra A, Povedano J, Astorga R, Gonzalez M, Silva H, Garcia-Pesquera F, Casanueva F, Dieguez C. The growth hormone releasing hormone (GH) – GH – Insulin Like growth factor 1 axis in patients with fibromyalgia syndrome. J Clin Endocrinol Metab. 1999 84:3378-3381. 56. Ferracioli G, Guerra P, Rizzi V, Baraldo M, Salaffi F, Furlanut M, Bartoli E. Somatomedin C (insulin growth factor 1) levels decrease during acute changes of stress related hormones. Relevance for fibromyalgia. J Rheumatol. 1994 21:2125-2130 57. Branco J, Atalaia A, Paiva T. Sleep cycles and alpha-delta sleep in fibromyalgia syndrome. J Rheumatol. 1994 Jun 21(6):1113-7. 58. Harding SM. Sleep in fibromyalgia patients: subjective and objective findings. Am J Med Sci. 1998 Jun 315(6):367-76. 59. Roizenblatt S, Moldofsky H, Benedito-Silva AA, Tufik S. Alpha sleep characteristics in fibromyalgia. Arthritis Rheum. 2001 Jan 44(1):222-30. 60. Wallymahmed ME, Baker GA, Humphris G, Dewey M, MacFarlane IA. The development, reliability and validity of a disease specific quality life model for adults with growth hormone deficiency. Clin Endocrinol (Oxf). 1996 44:403-411. 61. Cuneo RC, Solomon F, McGauley GA, Sonksen PH. The growth hormone deficiency syndrome in adults. Clin Endocrinol (Oxf). 1992 37:387-397. As possíveis fontes fisiopatológicas da fibromialgia e suas importâncias como alvos para tratamento RBM – Rev. Bras. Med. – Vol. 66 – Edição Suplementar – nº 2 – Abril/2009 9 62. Ayuk J, Sheppard MC. Growth hormone and its disorders. Postgrad Med J. 2006 Jan 82(963):24-30. 63. Florini JR. Hormonal control of muscle growth. Muscle nerve. 1987 10:577- 598. 64. Bennett RM, Clark SC, Walczyk J. A randomized, double-blind, placebocontrolled study of growth hormone in the treatment of fibromyalgia. Am J Med. 1998 Mar 104(3):227-31. 65. Shuer ML. Fibromyalgia: symptom constellation and potential therapeutic options. Endocrine. 2003 Oct 22(1):67-76. 66. Leal-Cerro A, Povedano J, Astorga R, Gonzalez M, Silva H, Garcia-esquera F, Casanueva FF, Dieguez C. The growth hormone (GH)-releasing hormone- GH-insulin-like growth factor-1 axis in patients with fibromyalgia syndrome. J Clin Endocrinol Metab. 1999 Sep 84(9):3378-81. 67. Crofford LJ, Pillemer SR, Kalogeras KT, Cash JM, Michelson D, Kling MA, Sternberg EM, Gold PW, Chrousos GP, Wilder RL. Hypothalamic-pituitaryadrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum. 1994 Nov 37(11):1583-92. 68. Griep EN, Boersma JW, Lentjes EG, Prins AP, van der Korst JK, de Kloet ER. Function of the hypothalamic-pituitary-adrenal axis in patients with fibromyalgia and low back pain. J Rheumatol. 1998 Jul 25(7):1374-1381. 69. Griep EN, Boersma JW, de Kloet ER. Altered reactivity of the hypothalamic- pituitary-adrenal axis in the primary fibromyalgia syndrome. J Rheumatol. 1993 Mar 20(3):469-474. 70. Giustina A, Romanelli G, Candrina R, Giustina G. Growth hormone deficiency in patients with idiopathic adrenocorticotropin deficiency resolves during glucocorticoid ment. J Clin Endocrinol Metab 1989 68:120- 4. 71. Dessein PH, Shipton EA, Joffe BI, Hadebe DP, Stanwix AE, Van der Merwe BA. Hyposecretion of adrenal androgens and the relation of serum adrenal steroids, serotonin and insulin-like growth factor-1 to clinical features in women with fibromyalgia. Pain. 1999 Nov 83(2):313-9. 72. Riedel W, Layka H, Neeck G. Secretory pattern of GH, TSH, thyroid hormones, ACTH, cortisol, FSH, and LH in patients with fibromyalgia syndrome following systemic injection of the relevant hypothalamic-releasing hormones. Z Rheumatol. 1998 57 Suppl 2:81-7. 73. El Maghraoui A, Tellal S, Achemlal L, Nouijai A, Ghazi M, Mounach A, Bezza A, Derouiche el M. Bone turnover and hormonal perturbations in patients with fibromyalgia. Clin Exp Rheumatol. 2006 Jul-Aug 24(4):428- 31. 74. Waxman J, Zatzkis SM. Fibromyalgia and menopause. Examination of the relationship. Postgrad Med. 1986 Sep 15 80(4):165-7, 170-1. 75. Okifuji A, Turk DC. Sex hormones and pain in regularly menstruating women with fibromyalgia syndrome. J Pain. 2006 Nov 7(11):851-9. 76. Macfarlane TV, Blinkhorn A, Worthington HV, Davies RM, Macfarlane GJ. Sex hormonal factors and chronic widespread pain: a population study among women. Rheumatology (Oxford). 2002 Apr 41(4):454-7. 77. Kugaya A, Epperson CN, Zoghbi S, van Dyck CH, Hou Y, Fujita M, Staley JK, Garg PK, Seibyl JP, Innis RB. Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women. American Journal of Psychiatry 2003 160: 1522-4. 78. McQueen JK, Wilson H, Fink G. Estradiol-17 beta increases serotonin transporter (SERT) mRNA levels and the density of SERT-binding sites in female rat brain. Brain Res Mol Brain Res. 1997 Apr 45(1):13-23. 79. Lu NZ, Eshleman AJ, Janowsky A, Bethea CL. Ovarian steroid regulation of serotonin reuptake transporter (SERT) binding, distribution, and function in female macaques. Mol Psychiatry. 2003 Mar 8(3):353-60. 80. Aloisi AM. Gonadal hormones and sex differences in pain reactivity. Clin J Pain. 2003 May-Jun 19(3):168-74. 81. E R Brown, K A Roth, J E Krause. Sexually dimorphic distribution of substance P in specific anterior pituitary cell populations. Proc Natl Acad Sci U S A. 1991 February 15 88(4): 1222–1226. 82. Schwarz MJ,Offenbaecher M, Neumeister A, Ewert T, Willeit M, Praschak- Rieder N, Zach J, Zacherl M, Lossau K, Weisser R, Stucki G, Ackenheil M. Evidence for an altered tryptophan metabolism in fibromyalgia. Neurobiol Dis. 2002 Dec 11(3):434-42. 83. Yunus MB, Dailey JW, Aldag JC, Masi AT, Jobe PC. Plasma tryptophan and other amino acids in primary fibromyalgia: a controlled study. J Rheumatol. 1992 Jan 19(1):90-4. 84. Russell IJ, Vipraio GA, Acworth I. Abnormalities in the central nervous system metabolism of tryptophan to 3-hydroxy kyneurenine in fibromyalgia syndrome. Arthrits Rheum. 1993 36:222 85. Miller LJ, Kubes KL. Serotonergic agents in the treatment of fibromyalgia syndrome. Ann Pharmacother. 2002 Apr 36(4):707-12. 86. Sayar K,Aksu G, Ak I, Tosun M. Venlafaxine treatment of fibromyalgia. Ann Pharmacother. 2003 Nov 37(11):1561-5. 87. Arnold LM,Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004 Sep 50(9):2974-84. 88. Vaeroy H, Helle R, Forre O, Kass E, Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain. 1988 Jan 32(1):21-6. 89. Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, Lopez Y, MacKillip F. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum. 1994 Nov 37(11):1593- 601. 90. Bradley LA, Alberts KR, Alarcon GS, Alexander MT, Mountz JM, Weigent DA, Lin HG, Blalock JE, Aaron LA, Alexander RW, San Pedro EC, Martin MY, Morell AC. Abnormal brain regional cerebral blood flow (rCBF) and cerebrospinal fluid (CSF) levels of substance P in patients and non patients with fibromyalgia (FM). Arthritis Rheum. 1996 Suppl 9:212. 91. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum. 1992 May 35(5):550-6. 92. Legangneux E, Mora JJ, Spreux-Varoquaux O, Thorin I, Herrou M, Alvado G, Gomeni C. Cerebrospinal fluid biogenic amine metabolites, plasmarich platelet serotonin and (3H)imipramine reuptake in the primary fibromyalgia syndrome. Rheumatology (Oxford). 2001 Mar 40(3):290-6. 93. Patrick B. Wood , James C. Patterson II, John J. Sunderland, Kerrie H. Tainter, Michael F. Glabus and David L. Lilien. Reduced Presynaptic Dopamine Activity in Fibromyalgia Syndrome Demonstrated With Positron Emission Tomography: A Pilot Study. J Pain 2007 Jan 8(1):51-8. 94. Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum. 2005 Aug 52(8):2495-505. 95. Holman AJ. Treatment of fibromyalgia with the dopamine agonist ropinirole: a 14-week double-blind pilot randomized controlled trial with 14-week blinded extension. American College of Rheumatology meeting San Antonio, TX Oct 16-21, 2004 Abstract 1870. 96. Lowe JC, Yellin J, Honeyman-Lowe G. Female fibromyalgia patients: lower resting metabolic rates than matched healthy controls. Med Sci Monit. 2006 Jul 12(7):CR282-9. 97. Lowe, J.C., Honeyman, G., and Yellin, J.: Lower resting metabolic rate and basal body temperature of fibromyalgia patients compared to matched healthy controls. Thyroid Science. 2006 1(8):1-18. 98. Lowe JC. Thyroid status of 38 fibromyalgia patients: implications for the etiology of fibromyalgia. http://www.drlowe.com/jcl/biojcl.htm Clinical Bulletin of Myofascial Therapy. 1997 2(1):47-64. 99. Lowe JC, Honeyman GS, Yellin J. Thyroid status of fibromyalgia patients. Clinical Bulletin of Myofascial Therapy. 1998 3(1):47-53. 100. Neeck G, Riedel W: Thyroid function in pacients with fibromyalgia syndrome. J Rheumatol. 1992 19: 1120-1122. 101. Ferraccioli G, Cavalieri F, Salaffi F et al: Neuroendocrinologic findings in primary fibromyalgia (soft tissue chronic pain syndrome) and in other chronic rheumatic conditions (rheumatoid arthritis, low back pain). J Rheumatol. 1990 17: 869-873. 102. Lowe JC, Cullum ME, Graf LH Jr, Yellin J. Mutations in the c-erbA beta 1 gene: do they underlie euthyroid fibromyalgia? Med Hypotheses. 1997 Feb 48(2):125-35. 103. Ribeiro LS, Proietti FA. Interrelations between fibromyalgia, thyroid autoantibodies, and depression. J Rheumatol. 2004 Oct 31(10):2036-40. 104. Pamuk ON, Cakir N. The frequency of thyroid antibodies in fibromyalgia patients and their relationship with symptoms. Clin Rheumatol. 2007 Jan 26(1):55-9. 105. Lowe, J.C., Garrison, R.L., Reichman, A.J., and Yellin, J.: Triiodothyronine (T3) treatment of euthyroid fibromyalgia: a small-N replication of a doubleblind placebo-controlled crossover study (abstract). Clin. Bull. Myofascial Ther. 1997 3(14):23-24. 106. Lowe, J.C. Results of an open trial of T3 therapy with 77 euthyroid female fibromyalgia patients. Clin. Bull. Myofascial Ther. 1997 2 (1):35-37. 107. Teitelbaum J, Bird B, Greenfield RM et al. Effective treatment of CFS and FMS: a randomized, double-blind placebo controlled study. J. Chron. Fatigue Synd., 8(2):3-28, 2001. 108. Mennemeier M, Garner RD, Heilman KM. Memory, mood and measurement in hypothyroidism. J Clin Exp Neuropsychol. 1993 Sep 15(5):822-31. Alambert, P.A. et al. 10 RBM – Rev. Bras. Med. – Vol. 66 – Edição Suplementar – nº 2 – Abril/2009 109. Jonassen JA, Mullikin-Kilpatrick D, McAdam A, Leeman SE. Thyroid hormone status regulates preprotachykinin-A gene expression in male rat anterior pituitary. Endocrinology. 1987 Oct 121(4):1555-61. 110. Jones PM, Ghatei MA, Wallis SC, Bloom SR. Differential response of neuropeptide Y, substance P and vasoactive intestinal polypeptide in the rat anterior pituitary gland to alterations in thyroid hormone status. J Endocrinol. 1994 Nov 143(2):393-7. 111. Savard P, Merand Y, Bedard P, Dussault JH, Dupont A. Comparative effects of neonatal hypothyroidism and euthyroidism on TRH and substance P content of lumbar spinal cord in saline and PCPA-treated rats. Brain Res. 1983 Oct 31 277(2):263-8. 112. Savard P, Blanchard LM, Merand Y, Bedard P, Dussault JH, Dupont A. Influences of both thyroid and bovine growth hormones on substance P, thyrotropin- releasing hormone, serotonin and 5-hydroxyindoleacetic acid contents in the lumbar spinal cord of developing rats. Brain Res. 1984 Mar 315(1):105-10. 113. Dupont A, Dussault JH, Rouleau D, DiPaolo T, Coulombe P, Gagne B, Merand Y, Moore S, Barden N. Effect of neonatal thyroid deficiency on the catecholamine, substance P, and thyrotropin-releasing hormone contents of discrete rat brain nuclei. Endocrinology. 1981 Jun 108(6):2039- 45. 114. Hammond DL. Control systems for afferent processing: the descending inhibitory pathways. In: Yaksh TL, ed. Spinal afferent processing. New york: Plenum Press. 1986 363-390. 115. Dubner R, Bennett GJ. Spinal and trigeminal mechanisms of nociception. Annu Rev Neurosci. 1983 6:381-418. 116. Archer T, Jonsson G, Minor BG, Post C. Noradrenergic-serotonergic interactions and nociception in the rat. Eur J Pharmacol. 1986 Jan 29 120(3):295-307. 117. de Lonlay A, Blouquit MF, Valens M et al. Tyrosine hydroxylase and dopamine â-hydroxylase inductions evoked by reserpine in the superior cervical ganglion of developing eu- and hypothyroid rats. J Auton Nerv Syst. 1991 36:33-38. 118. Claustre J, Balende C, Pujol JF. Influence of the thyroid hormone status on tyrosine hydroxylase in central and peripheral catecholaminergic structures. Neurochem Int. 1996 Mar 28(3):277-81. 119. Mano T, Sakamoto H, Fujita K, Makino M, Kakizawa H, Nagata M, Kotake M, Hamada M, Uchimura K, Hayakawa N, Hayashi R, Nakai A, Itoh M, Kuzuya H, Nagasaka A. Effects of thyroid hormone on catecholamine and its metabolite concentrations in rat cardiac muscle and cerebral cortex. Thyroid. 1998 Apr 8(4):353-8. 120. Constant EL, de Volder AG, Ivanoiu A, Bol A, Labar D, Seghers A, Cosnard G, Melin J, Daumerie C. Cerebral blood flow and glucose metabolism in hypothyroidism: a positron emission tomography study. J Clin Endocrinol Metab. 2001 Aug 86(8):3864-70. 121. Nagamachi S, Jinnouchi S, Nishii R, Ishida Y, Fujita S, Futami S, Kodama T, Tamura S, Kawai K. Cerebral blood flow abnormalities induced by transient hypothyroidism after thyroidectomy – analysis by tc-99m-HMPAO and SPM96. Ann Nucl Med. 2004 Sep 18(6):469-77. 122. Kales A, Heuser G, Jacobson A, Kales JD, Hanley J, Zweizig JR, Paulson MJ. All night sleep studies in hypothyroid patients, before and after treatment. J Clin Endocrinol Metab. 1967 Nov 27(11):1593-9. 123. Kales JD, Kales A. Nocturnal psychophysiological correlates of somatic conditions and sleep disorders. Int J Psychiatry Med. 1975 6(1-2):43-62. 124. Schmid C, Zwimpfer C, Brandle M, Krayenbuhl PA, Zapf J, Wiesli P. Effect of thyroxine ment on serum IGF-I, IGFBP-3 and the acid-labile subunit in patients with hypothyroidism and hypopituitarism. Clin Endocrinol (Oxf). 2006 Dec 65(6):706-11. 125. Laron Z. Interactions between the thyroid hormones and the hormones of the growth hormone axis. Pediatr Endocrinol Rev. 2003 Dec 1 Suppl 2:244- 9-discussion 250. 126. Cabello G, Wrutniak C. Thyroid hormone and growth: relationships with growth hormone effects and regulation. Reprod Nutr Dev. 1989 29(4):387- 402. 127. Lovy MR, Starkebaum G, Uberoi S: Hepatitis C infection presenting with rheumatic manifestations: a mimic of rheumatoid arthritis. J Rheumatol. 1996 23: 979-83. 128. Rivera J, De Diego A, Trinchet M, Garcia Monforte A: Fibromyalgia associated hepatitis C virus infection. Br J Rheumatol. 1997 36:981-85. 129. Buskila D, Shnaider A, Neumann L et al: Musculoskeletal manifestations and autoantibody profile in 90 hepatitis C virus infected Israeli patients. Semin Arthritis Rheum. 1998 28:107-13. 130. Gur A, Karakoc M, Nas K, Remzi, Cevik, Denli A, Sarac J. Cytokines and depression in cases with fibromyalgia. J Rheumatol. 2002 Feb 29(2):358-61. 131. Gur A,Karakoc M,Erdogan S,Nas K,Cevik R,Sarac AJ. Regional cerebral blood flow and cytokines in young females with fibromyalgia. Clin Exp Rheumatol. 2002 Nov-Dec 20(6):753-60. 132. Wallace DJ, Bowman RL, Wormsley SB, Peter JB. Cytokines and immune regulation in patients with fibrositis. Arthritis Rheum. 1984 32:1334-1335. 133. Hader N, Rimon D, Kinarty A, Lahat N. Altered interleukin-2 secretion in patients with fibromyalgia syndrome. Arthritis Rheum 1991 34:866-72. 134. Maes M, Libbrecht I, Van Hunsel F, Lin AH, De Clerck L,Stevens W, et al. The immune-inflammatory pathophysiology of fibromyalgia: increased serum soluble gp130, the common signal transducer protein of various neurotrophic cytokines. Psychoneuroendocrinology. 1999 May 24(4):371- 83. 135. Salemi S,Rethage J, Wollina U, Michel BA, Gay RE, Gay S,Sprott H. Detection of interleukin-1beta (IL-1beta), IL-6, and tumor necrosis factor-alpha in skin of patients with fibromyalgia. J Rheumatol. 2003 Jan 30(1):146- 50. 136. Cunha FQ, Lorenzetti BB, Poole S, Ferreira SH. Interleukin-8 as a mediator of sympathetic pain. Br J Pharmacol. 1991 Nov 104(3):765-7. 137. Wichers M, Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol. 2002 Dec 5(4):375-88. 138. Junger H, Sorkin LS. Nociceptive and inflammatory effects of subcutaneous TNFalpha. Pain. 2000 85:145-151. 139. Malcangio M, Bowery NG, Flower RJ, Perretti M. Effect of interleukin-1 beta on the release of substance P from rat isolated spinal cord. Eur J Pharmacol. 1996 Mar 28 299(1-3):113-8. 140. Suzuki, H., T. M. Kundig, C. Furlonger, A. Wakeham, E. Tomms, T. Matsuyama, R. Schmits, J. J. L. Simard, P. S. Ohashi, H. Griesser, et al. Deregulated T cell activation and autoimmunity in mice lacking interleucin- 2 receptor β. Science. 1995 268:1472. 141. Cuesta MC, Quintero L, Pons H, Suarez-Roca H. Substance P and calcitonin gene-related peptide increase IL-1-beta, IL-6 and TNF-alpha secretion from human peripheral blood mononuclear cells. Neurochem Int. 2002 40:301–306. 142. Sadlack B, Löhler J, Schorle H, Klebb G, Haber H, Sickel E, et al. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur. J. Immunol. 1995 Nov 25(11):3053-9. 143. Jiang CL, Xu D, Lu CL, Wang YX, You ZD, Liu XY. Interleukin-2: structural and biological relatedness to opioid peptides. Neuroimmunomodulation. 2000 8(1):20-4. 144. Jiang CL. A new domain of interleukin-2 and its analgesic effect in central nervous system. Sheng Li Ke Xue Jin Zhan. 1996 Apr 27(2):143-5. 145. Blanco LE, de Serres FJ, Fernandez-Bustillo E, Kassam DA, Arbesu D, Rodriguez C, Torre JC. alpha1-Antitrypsin and fibromyalgia: new data in favour of the inflammatory hypothesis of fibromyalgia. Med Hypotheses. 2005 64(4):759-69. 146. Yunus MB, Masi AT, Aldag JC. Short term effects of ibuprofen in primary fibromyalgia syndrome: a double-blind, placebo controlled trial. J Rheumatol. 1989 16:527-32. 147. Clark S, Tindall E, Bennett RM. A double blind crossover trial of prednisone versus placebo in the treatment of fibrositis. J Rheumatol. 1985 12:980-3. 148. Lautenschlager J. Present state of medication therapy in fibromyalgia syndrome. Scand J Rheumatol Suppl. 2000 113:32-6. 149. Schug SA. Combination analgesia in 2005-a rational approach: focus on paracetamol-tramadol. Clin Rheumatol. 2006 25(1):16-21. 150. Fossaluzza V, De Vita S. Combined therapy with cyclobenzaprine and ibuprofen in primary fibromyalgia syndrome. Int J Clin Pharmacol Res. 1992 12(2):99-102. 151. Wood PB. A reconsideration of the relevance of systemic low-dose ketamine to the pathophysiology of fibromyalgia. J Pain. 2006 Sep 7(9):611-4. 152. Henriksson KG, Sorensen J. The promise of N-methyl-D-aspartate receptor antagonists in fibromyalgia. Rheum Dis Clin North Am. 2002 May 28(2):343-51. 153. Sorensen J, Bengtsson A, Backman E, Henriksson KG, Bengtsson M. Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine, and ketamine. Scand J Rheumatol. 1995 24(6):360-5 |
![]() |